Transcode Therapeutics Inc (RNAZ) - Total Assets
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) holds total assets worth $157.16 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Transcode Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Transcode Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Transcode Therapeutics Inc (RNAZ) total market value for the company's overall valuation and market capitalisation.
Transcode Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Transcode Therapeutics Inc's total assets of $157.16 Million consist of 13.5% current assets and 86.5% non-current assets. Review RNAZ liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $3.25 Million | 2.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $114.30 Million | 70.4% |
| Goodwill | $25.74 Million | 15.9% |
Asset Composition Trend (2018–2025)
This chart illustrates how Transcode Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Transcode Therapeutics Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Transcode Therapeutics Inc's current assets represent 13.5% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 99.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 85.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 70.4% of total assets.
Transcode Therapeutics Inc Competitors by Total Assets
Key competitors of Transcode Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Transcode Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.11 | 5.20 | 0.35 |
| Quick Ratio | 3.11 | 5.20 | 0.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $11.37 Million | $10.53 Million | $-992.88K |
Transcode Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Transcode Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 2126.3% |
| Total Assets | $162.40 Million |
| Market Capitalization | $1.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Transcode Therapeutics Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Transcode Therapeutics Inc's assets grew by 2126.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Transcode Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $162.40 Million | +2126.32% |
| 2024-12-31 | $7.29 Million | +41.10% |
| 2023-12-31 | $5.17 Million | -31.87% |
| 2022-12-31 | $7.59 Million | -66.92% |
| 2021-12-31 | $22.94 Million | +2073.50% |
| 2020-12-31 | $1.06 Million | +386.92% |
| 2019-12-31 | $216.74K | +0.98% |
| 2018-12-31 | $214.65K | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastati… Read more